All In Biotech

Drug Trial Radar · NCT02480374

Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer

A Phase I Study of the Safety and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Standard Neoadjuvant Chemotherapy in Patients Newly Diagnosed with Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Last checked: Nov 19, 2026Latest source record: Oct 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Sep 2015

Primary completion

May 2017

Study completion May 2017

Sponsor

Lead sponsor
ImunonIndustry
Sponsor type
Industry
First posted
Jun 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This dose escalation study will determine a maximum tolerated dose and/or optimal biological dose of GEN-1 for carboplatin/paclitaxel combination in newly diagnosed ovarian cancer.

Conditions

  • Epithelial Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer

Interventions

  • IMNN-001Biological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: 4 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama Birmingham Cancer Center

    Birmingham, Alabama

  • Washington Univ. in St. Louis/Barnes Jewish Hospital

    St Louis, Missouri

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Medical College of Wisconsin/Froedtert Hospital

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.